Actinogen Medical Ltd ACW
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- A$0.04
- Day Range
- A$0.04–0.05
- 52-Week Range
- A$0.03–0.07
- Bid/Ask
- A$0.04 / A$0.04
- Shares Outstanding
- 3.87B
- Market Cap
- A$162.72M
- Volume/Avg
- 5M / 5M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Actinogen Medical Ltd is a biotechnology company. The company develops a novel therapy for neurological and neuropsychiatric diseases associated with dysregulated cortisol in the brain. It is focused on the clinical development of Xanamem, an oral medication for neurological diseases amenable to its mechanism of lowering cortisol in brain cells. Geographically, the company's income is derived in Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- —
- Website
- https://www.actinogen.com.au
Valuation
|
Metric
|
ACW
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 7.30 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ACW
|
|---|---|
Quick Ratio | 3.44 |
Current Ratio | 3.45 |
Interest Coverage | — |
Quick Ratio
ACW
Profitability
|
Metric
|
ACW
|
|---|---|
Return on Assets (Normalized) | −63.38% |
Return on Equity (Normalized) | −85.21% |
Return on Invested Capital (Normalized) | −72.89% |
Return on Assets
ACW
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|jHbt<F | LOCK|&>rN | $142B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|#t@QLG> | LOCK|T#lS | $96B | |||
| Moderna Inc
MRNA
| LOCK|D#tvQz | LOCK|!#k | $89B | |||
| argenx SE ADR
ARGX
| LOCK|KzJK#KV | LOCK|&! | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|nZ?$<@ | LOCK|#c | $43B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|zjwLFsW | LOCK|qs?w# | $30B | |||
| Incyte Corp
INCY
| LOCK|qh^Fv&s | LOCK|ST | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|cLsB<% | LOCK|p& | $22B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|QtgNS& | LOCK|&tWLF | $22B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|RMdGfx | LOCK|>l$ | $15B |
United States